Re: Glaxo denies pushing 'lifestyle' treatments

April 28, 2006

Not always it can't. I tried.

>

> Restless legs are easily fixed with a mix of calcium and magnesium

with a

> little acid like some apple cider vinegar. All of which is natural

and has

> no side effects. Adele wrote extensively about nutrients for

handling

> different things back in the 50's and 60's and the stuff still

works now!

>

> http://business.guardian.co.uk/story/0,,1763199,00.html

>

> Glaxo denies pushing 'lifestyle' treatments

> · 'Restless leg syndrome can ruin people's lives'

> · British drug firms' figures outstrip expectations

>

> Fiona Walsh

> Friday April 28, 2006

>

> Guardian

>

> GlaxoKline, Europe's biggest drugs manufacturer, yesterday

defended

> itself against accusations that it is turning healthy people into

patients

> by " disease mongering " and pushing " lifestyle " treatments for

little-known

> ailments.

> Studies published in a respected medical journal, the Public

Library of

> Science Medicine, this month accused the big pharmaceutical

companies of

> " medicalising " problems such as high cholesterol and sexual

dysfunction. The

> authors of the report highlighted the " restless legs " syndrome,

described by

> GSK as " common yet unrecognised " when it launched its Ropinirole

treatment

> last year.

>

> Stout, head of GSK's pharmaceutical operations, yesterday

denied the

> accusations, saying: " You need to talk to the patients. Things like

restless

> leg syndrome can ruin people's lives. It is easy to trivialise

things when

> you don't have them. If people did not want the treatments, they

would not

> seek them. "

>

> His comments came as GSK and rivals AstraZeneca and Shire

Pharmaceuticals,

> Britain's three leading drugs groups, released forecast-busting

figures for

> their first quarters. At GSK, profits for the three months to end

March

> jumped by 27% to £2.17bn on sales 15% ahead at £5.81bn. Stripping

out

> currency effects, the increase was 17%.

>

> Behind the better than expected results was a strong performance

from the

> group's more established drugs, including its biggest seller, the

asthma

> medicine Advair, which saw sales rise by 12% to £816m. Vaccines,

including

> its influenza vaccine, also turned in a strong performance, pushing

profits

> ahead by 44% to £366m. The group has also begun clinical trials on

its H5N1

> vaccine for bird flu.

>

> GSK is regarded as having one of the strongest new drugs pipelines

in the

> industry, including two potential blockbuster cancer drugs -

Cervarix, a

> vaccine for the prevention of cervical cancer, and Tykerb, a breast

cancer

> pill, both of which are expected to be launched next year.

>

> GSK declined to comment specifically on whether it will bid for

Pfizer's

> over-the-counter medicines business, put up for auction in

February. GSK

> chief executive Jean-Pierre Garnier said: " Our eyes are open to all

> opportunities. "

>

> At AstraZeneca, Britain's second-largest drugs group, results also

topped

> analysts' expectations. First quarter profits surged by 35% to just

over

> $2bn (£1.1bn) pre-tax, on sales 12% ahead at $6.18bn. Earnings were

ahead by

> 40%, to 90 cents a share. Its biggest-selling drug, the Nexium ulcer

> treatment, saw sales rise by 16% to $1.2bn, while sales of

cholesterol

> treatment Crestor rose 45% to $387m. In total, its top five drugs

pushed

> sales ahead by 25%.

>

> Chief executive Brennan, who took over from Sir Tom McKillop

at the

> start of the year, also announced the latest in a flurry of deals

from the

> group. It has sold its US anaesthetic and analgesic product

portfolio to the

> US drug group Abraxis BioScience for $350m. It has signed a deal to

> co-promote Abraxis's chemotherapy product, Abraxane, in the US and

will pay

> $200m for the five and a half year agreement, as well as meeting

half the

> marketing costs. Mr Brennan said the group " continues to pursue

attractive

> external opportunities to strengthen our business " .

>

> Shire Pharmaceuticals saw its first quarter net income almost

quadruple,

> from $15.4m to $61.1m on the back of higher sales of its

hyperactivity

> treatment, Adderall XR. Sales were up 23% to $411m.

>

> Guardian Unlimited © Guardian Newspapers Limited 2006

>

April 28, 2006

Not always it can't. I tried.

>

> Restless legs are easily fixed with a mix of calcium and magnesium

with a

> little acid like some apple cider vinegar. All of which is natural

and has

> no side effects. Adele wrote extensively about nutrients for

handling

> different things back in the 50's and 60's and the stuff still

works now!

>

> http://business.guardian.co.uk/story/0,,1763199,00.html

>

> Glaxo denies pushing 'lifestyle' treatments

> · 'Restless leg syndrome can ruin people's lives'

> · British drug firms' figures outstrip expectations

>

> Fiona Walsh

> Friday April 28, 2006

>

> Guardian

>

> GlaxoKline, Europe's biggest drugs manufacturer, yesterday

defended

> itself against accusations that it is turning healthy people into

patients

> by " disease mongering " and pushing " lifestyle " treatments for

little-known

> ailments.

> Studies published in a respected medical journal, the Public

Library of

> Science Medicine, this month accused the big pharmaceutical

companies of

> " medicalising " problems such as high cholesterol and sexual

dysfunction. The

> authors of the report highlighted the " restless legs " syndrome,

described by

> GSK as " common yet unrecognised " when it launched its Ropinirole

treatment

> last year.

>

> Stout, head of GSK's pharmaceutical operations, yesterday

denied the

> accusations, saying: " You need to talk to the patients. Things like

restless

> leg syndrome can ruin people's lives. It is easy to trivialise

things when

> you don't have them. If people did not want the treatments, they

would not

> seek them. "

>

> His comments came as GSK and rivals AstraZeneca and Shire

Pharmaceuticals,

> Britain's three leading drugs groups, released forecast-busting

figures for

> their first quarters. At GSK, profits for the three months to end

March

> jumped by 27% to £2.17bn on sales 15% ahead at £5.81bn. Stripping

out

> currency effects, the increase was 17%.

>

> Behind the better than expected results was a strong performance

from the

> group's more established drugs, including its biggest seller, the

asthma

> medicine Advair, which saw sales rise by 12% to £816m. Vaccines,

including

> its influenza vaccine, also turned in a strong performance, pushing

profits

> ahead by 44% to £366m. The group has also begun clinical trials on

its H5N1

> vaccine for bird flu.

>

> GSK is regarded as having one of the strongest new drugs pipelines

in the

> industry, including two potential blockbuster cancer drugs -

Cervarix, a

> vaccine for the prevention of cervical cancer, and Tykerb, a breast

cancer

> pill, both of which are expected to be launched next year.

>

> GSK declined to comment specifically on whether it will bid for

Pfizer's

> over-the-counter medicines business, put up for auction in

February. GSK

> chief executive Jean-Pierre Garnier said: " Our eyes are open to all

> opportunities. "

>

> At AstraZeneca, Britain's second-largest drugs group, results also

topped

> analysts' expectations. First quarter profits surged by 35% to just

over

> $2bn (£1.1bn) pre-tax, on sales 12% ahead at $6.18bn. Earnings were

ahead by

> 40%, to 90 cents a share. Its biggest-selling drug, the Nexium ulcer

> treatment, saw sales rise by 16% to $1.2bn, while sales of

cholesterol

> treatment Crestor rose 45% to $387m. In total, its top five drugs

pushed

> sales ahead by 25%.

>

> Chief executive Brennan, who took over from Sir Tom McKillop

at the

> start of the year, also announced the latest in a flurry of deals

from the

> group. It has sold its US anaesthetic and analgesic product

portfolio to the

> US drug group Abraxis BioScience for $350m. It has signed a deal to

> co-promote Abraxis's chemotherapy product, Abraxane, in the US and

will pay

> $200m for the five and a half year agreement, as well as meeting

half the

> marketing costs. Mr Brennan said the group " continues to pursue

attractive

> external opportunities to strengthen our business " .

>

> Shire Pharmaceuticals saw its first quarter net income almost

quadruple,

> from $15.4m to $61.1m on the back of higher sales of its

hyperactivity

> treatment, Adderall XR. Sales were up 23% to $411m.

>

> Guardian Unlimited © Guardian Newspapers Limited 2006

>

April 28, 2006

Not always it can't. I tried.

>

> Restless legs are easily fixed with a mix of calcium and magnesium

with a

> little acid like some apple cider vinegar. All of which is natural

and has

> no side effects. Adele wrote extensively about nutrients for

handling

> different things back in the 50's and 60's and the stuff still

works now!

>

> http://business.guardian.co.uk/story/0,,1763199,00.html

>

> Glaxo denies pushing 'lifestyle' treatments

> · 'Restless leg syndrome can ruin people's lives'

> · British drug firms' figures outstrip expectations

>

> Fiona Walsh

> Friday April 28, 2006

>

> Guardian

>

> GlaxoKline, Europe's biggest drugs manufacturer, yesterday

defended

> itself against accusations that it is turning healthy people into

patients

> by " disease mongering " and pushing " lifestyle " treatments for

little-known

> ailments.

> Studies published in a respected medical journal, the Public

Library of

> Science Medicine, this month accused the big pharmaceutical

companies of

> " medicalising " problems such as high cholesterol and sexual

dysfunction. The

> authors of the report highlighted the " restless legs " syndrome,

described by

> GSK as " common yet unrecognised " when it launched its Ropinirole

treatment

> last year.

>

> Stout, head of GSK's pharmaceutical operations, yesterday

denied the

> accusations, saying: " You need to talk to the patients. Things like

restless

> leg syndrome can ruin people's lives. It is easy to trivialise

things when

> you don't have them. If people did not want the treatments, they

would not

> seek them. "

>

> His comments came as GSK and rivals AstraZeneca and Shire

Pharmaceuticals,

> Britain's three leading drugs groups, released forecast-busting

figures for

> their first quarters. At GSK, profits for the three months to end

March

> jumped by 27% to £2.17bn on sales 15% ahead at £5.81bn. Stripping

out

> currency effects, the increase was 17%.

>

> Behind the better than expected results was a strong performance

from the

> group's more established drugs, including its biggest seller, the

asthma

> medicine Advair, which saw sales rise by 12% to £816m. Vaccines,

including

> its influenza vaccine, also turned in a strong performance, pushing

profits

> ahead by 44% to £366m. The group has also begun clinical trials on

its H5N1

> vaccine for bird flu.

>

> GSK is regarded as having one of the strongest new drugs pipelines

in the

> industry, including two potential blockbuster cancer drugs -

Cervarix, a

> vaccine for the prevention of cervical cancer, and Tykerb, a breast

cancer

> pill, both of which are expected to be launched next year.

>

> GSK declined to comment specifically on whether it will bid for

Pfizer's

> over-the-counter medicines business, put up for auction in

February. GSK

> chief executive Jean-Pierre Garnier said: " Our eyes are open to all

> opportunities. "

>

> At AstraZeneca, Britain's second-largest drugs group, results also

topped

> analysts' expectations. First quarter profits surged by 35% to just

over

> $2bn (£1.1bn) pre-tax, on sales 12% ahead at $6.18bn. Earnings were

ahead by

> 40%, to 90 cents a share. Its biggest-selling drug, the Nexium ulcer

> treatment, saw sales rise by 16% to $1.2bn, while sales of

cholesterol

> treatment Crestor rose 45% to $387m. In total, its top five drugs

pushed

> sales ahead by 25%.

>

> Chief executive Brennan, who took over from Sir Tom McKillop

at the

> start of the year, also announced the latest in a flurry of deals

from the

> group. It has sold its US anaesthetic and analgesic product

portfolio to the

> US drug group Abraxis BioScience for $350m. It has signed a deal to

> co-promote Abraxis's chemotherapy product, Abraxane, in the US and

will pay

> $200m for the five and a half year agreement, as well as meeting

half the

> marketing costs. Mr Brennan said the group " continues to pursue

attractive

> external opportunities to strengthen our business " .

>

> Shire Pharmaceuticals saw its first quarter net income almost

quadruple,

> from $15.4m to $61.1m on the back of higher sales of its

hyperactivity

> treatment, Adderall XR. Sales were up 23% to $411m.

>

> Guardian Unlimited © Guardian Newspapers Limited 2006

>

April 28, 2006

Not always it can't. I tried.

>

> Restless legs are easily fixed with a mix of calcium and magnesium

with a

> little acid like some apple cider vinegar. All of which is natural

and has

> no side effects. Adele wrote extensively about nutrients for

handling

> different things back in the 50's and 60's and the stuff still

works now!

>

> http://business.guardian.co.uk/story/0,,1763199,00.html

>

> Glaxo denies pushing 'lifestyle' treatments

> · 'Restless leg syndrome can ruin people's lives'

> · British drug firms' figures outstrip expectations

>

> Fiona Walsh

> Friday April 28, 2006

>

> Guardian

>

> GlaxoKline, Europe's biggest drugs manufacturer, yesterday

defended

> itself against accusations that it is turning healthy people into

patients

> by " disease mongering " and pushing " lifestyle " treatments for

little-known

> ailments.

> Studies published in a respected medical journal, the Public

Library of

> Science Medicine, this month accused the big pharmaceutical

companies of

> " medicalising " problems such as high cholesterol and sexual

dysfunction. The

> authors of the report highlighted the " restless legs " syndrome,

described by

> GSK as " common yet unrecognised " when it launched its Ropinirole

treatment

> last year.

>

> Stout, head of GSK's pharmaceutical operations, yesterday

denied the

> accusations, saying: " You need to talk to the patients. Things like

restless

> leg syndrome can ruin people's lives. It is easy to trivialise

things when

> you don't have them. If people did not want the treatments, they

would not

> seek them. "

>

> His comments came as GSK and rivals AstraZeneca and Shire

Pharmaceuticals,

> Britain's three leading drugs groups, released forecast-busting

figures for

> their first quarters. At GSK, profits for the three months to end

March

> jumped by 27% to £2.17bn on sales 15% ahead at £5.81bn. Stripping

out

> currency effects, the increase was 17%.

>

> Behind the better than expected results was a strong performance

from the

> group's more established drugs, including its biggest seller, the

asthma

> medicine Advair, which saw sales rise by 12% to £816m. Vaccines,

including

> its influenza vaccine, also turned in a strong performance, pushing

profits

> ahead by 44% to £366m. The group has also begun clinical trials on

its H5N1

> vaccine for bird flu.

>

> GSK is regarded as having one of the strongest new drugs pipelines

in the

> industry, including two potential blockbuster cancer drugs -

Cervarix, a

> vaccine for the prevention of cervical cancer, and Tykerb, a breast

cancer

> pill, both of which are expected to be launched next year.

>

> GSK declined to comment specifically on whether it will bid for

Pfizer's

> over-the-counter medicines business, put up for auction in

February. GSK

> chief executive Jean-Pierre Garnier said: " Our eyes are open to all

> opportunities. "

>

> At AstraZeneca, Britain's second-largest drugs group, results also

topped

> analysts' expectations. First quarter profits surged by 35% to just

over

> $2bn (£1.1bn) pre-tax, on sales 12% ahead at $6.18bn. Earnings were

ahead by

> 40%, to 90 cents a share. Its biggest-selling drug, the Nexium ulcer

> treatment, saw sales rise by 16% to $1.2bn, while sales of

cholesterol

> treatment Crestor rose 45% to $387m. In total, its top five drugs

pushed

> sales ahead by 25%.

>

> Chief executive Brennan, who took over from Sir Tom McKillop

at the

> start of the year, also announced the latest in a flurry of deals

from the

> group. It has sold its US anaesthetic and analgesic product

portfolio to the

> US drug group Abraxis BioScience for $350m. It has signed a deal to

> co-promote Abraxis's chemotherapy product, Abraxane, in the US and

will pay

> $200m for the five and a half year agreement, as well as meeting

half the

> marketing costs. Mr Brennan said the group " continues to pursue

attractive

> external opportunities to strengthen our business " .

>

> Shire Pharmaceuticals saw its first quarter net income almost

quadruple,

> from $15.4m to $61.1m on the back of higher sales of its

hyperactivity

> treatment, Adderall XR. Sales were up 23% to $411m.

>

April 28, 2006

Jim,

I continue to find out how much influence the drug makers have. I have been

off work since Dec 2005, after fracturing my wrist into pieces. I have had a lot

of problems healing. The radial bone shortened preventing me from turning palms

up, up and down motion is forever decreased, and I have finger contractures. I

thought that I was going to get surgery to correct the shortening; but, the the

doctor said that I had classic RSD and referred me to a pain doctor. They want

to give me nerve blocks in my neck; and have me sign a document agreeing to take

narcotics and agreeing to be tested to be sure the drugs are taken. I told them

I did not want drugs, I just want my arm and hand fixed. Now, all are pressing

me to comply.

April 28, 2006